Search > Non-Hodgkin's Lymphoma
49 Participants NeededMy employer runs this trial

GSK5926371 for Non-Hodgkin's Lymphoma

Recruiting at 19 trial locations
Age: 18+
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: GlaxoSmithKline
Must not be taking: Immunosuppressants, CAR-T, Bispecific antibodies
Disqualifiers: Other malignancies, CNS disease, others
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

The goal of this clinical trial is to learn if drug GSK5926371 works to treat a form of B-cell cancer (a type of blood cancer) that has returned or failed to respond to prior therapies in adults. The study will primarily assess the drugs safety and tolerability in participants. Additionally, it seeks to determine the clinical efficacy and pharmacokinetic (PK) properties of GSK5926371.

Are You a Good Fit for This Trial?

This trial is for adults with B-cell non-Hodgkin's lymphoma that has come back or not responded to at least two previous treatments, including one with anti-CD20 drugs. Participants must have measurable disease, good organ function, and be able to care for themselves most of the time.

Inclusion Criteria

I have relapsed or refractory B-cell non-Hodgkin lymphoma needing treatment.
I have a tumor or lesion that can be measured by scans or exams.
I have had at least two previous cancer treatments, including one with anti-CD20 therapy.
See 4 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive GSK5926371 to assess safety, tolerability, and clinical efficacy

Up to approximately 169 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • GSK5926371

Trial Overview

The study is testing a new drug called GSK5926371 in people whose B-cell lymphoma has returned or resisted treatment. The main focus is on safety and how well the drug works. All participants receive GSK5926371.

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: GSK5926371Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

GlaxoSmithKline

Lead Sponsor

Trials
4,834
Recruited
8,389,000+
Headquarters
London, UK
Known For
Vaccines & Medicines
Top Products
**Advair (salmeterol, fluticasone propionate)**, **Shingrix (shingles vaccine)**, **Augmentin (amoxicillin/clavulanate potassium)**, **Ventolin (salbutamol sulfate)
Dame Emma Walmsley profile image

Dame Emma Walmsley

GlaxoSmithKline

Chief Executive Officer since 2017

MA in Classics and Modern Languages from Oxford University

Dr. Hal Barron profile image

Dr. Hal Barron

GlaxoSmithKline

Chief Medical Officer since 2018

MD from Harvard Medical School

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.